CalciMedica, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies. The company’s Form 8-K reports cover results of operations and financial condition, clinical program events involving Auxora, and related updates for inflammatory and immunologic disease programs.
The filing record also includes capital-structure and governance disclosures, including Nasdaq continued-listing compliance matters, at-the-market offering documentation, shareholder voting matters, and the company’s common stock registration on The Nasdaq Capital Market under the symbol CALC.
CalciMedica insider purchase and holdings summary. Eric W. Roberts, who is listed as a director, a 10% owner and Chief Business Officer, reported a purchase of 2,343 shares of CalciMedica common stock on 09/09/2025 at a weighted average price of $3.1488 (price range $2.75–$3.21). The filing lists total beneficial ownership following the reported transactions across multiple accounts and entities: 73,250 shares (FMTC Custodian Roth IRA), 179,706 shares disposed, 49,894 shares (Oppenheimer custodian Roth IRA), 10,661 shares (IRA Financial Trust), 356,989 shares (Valence Investments SPV IV, LLC), 66,228 shares (Valence Investments SPV V, LLC), and 316,109 shares (Valence Investments SPV VI, LLC). The filer signed through an attorney-in-fact.
CalciMedica, Inc. Schedule 13G/A clarifies that a group led by Avenue Venture Opportunities Fund II and affiliated entities reports beneficial ownership of 1,359,553 shares, representing 8.87% of the issuer on a fully diluted basis (13,972,177 shares). The reported position includes 718,390 shares issuable upon conversion of a $2.0 million loan and 641,163 shares issuable upon exercise of warrants.
The Loan and Security Agreement closed on February 28, 2025 for up to $32 million in three tranches; Tranche I funded at closing, Tranche II is available between September 1, 2025 and March 31, 2026 and remained unfunded at the amendment date. The amendment reports that the actual number of common shares held as of the filing is 1,000,358 shares and clarifies conversion rights and voting/dispositive power among the reporting persons.
CalciMedica, Inc. disclosed that a group led by Avenue Venture Opportunities Fund II, L.P. beneficially owns 1,359,553 shares of common stock, representing 8.87% of the fully diluted class based on 13,972,177 shares. The reported holdings include 718,390 shares issuable upon conversion of a $2.0 million loan convertible at a per‑share price of $2.784 and 641,163 shares issuable upon exercise of outstanding warrants. Avenue Capital Management II, L.P. is the manager with sole voting and dispositive power over the Fund's shares but disclaims direct beneficial ownership except to the extent of pecuniary interest. The filing provides required ownership disclosure and related certifications.
CalciMedica director, chief business officer, and 10% owner Eric W. Roberts reported open‑market purchases of CalciMedica common stock through a Roth IRA. On August 28, 2025, an FMTC‑custodied Roth IRA for his benefit bought 9,200 shares at a weighted average price of $2.863, with trade prices ranging from $2.75 to $2.92. On August 29, 2025, the same Roth IRA bought an additional 800 shares at $2.74 per share, bringing that account’s holdings to 70,907 shares.
After these transactions, Roberts is shown as directly owning 179,706 shares and indirectly owning additional CalciMedica shares through multiple custodial and investment vehicles, including Roth IRAs and Valence Investments special purpose vehicles.
CalciMedica, Inc. director, chief business officer, and 10% owner Eric W. Roberts reported an open-market purchase of 3,508 shares of common stock on August 21, 2025 at a weighted average price of $2.7928 per share. The purchased shares are held indirectly through an FMTC Custodian Roth IRA for his benefit, which now holds 60,907 shares after the transaction.
CalciMedica insider filing shows purchases and an option exercise increasing reported holdings. Eric W. Roberts reported purchases of 1,000 shares on 08/19/2025 at $2.79 and 2,000 shares on 08/20/2025 at $2.72. He also exercised an employee stock option for 15,000 shares at an exercise price of $1.53 on 08/20/2025.
The filing lists multiple custodial and indirect holdings across Roth IRA accounts and several Valence Investments SPVs, and shows 57,750 derivative securities reported as beneficially owned following the transactions.
CalciMedica insider purchase reported: The company's Chief Medical Officer, Sudarshan Hebbar, reported buying 9,563 shares of CalciMedica, Inc. (ticker: CALC) on 08/19/2025 at a weighted average purchase price of $2.8194, with individual trade prices ranging from $2.74 to $2.86. After the transaction, the reporting person beneficially owned 61,539 shares held directly. The Form 4 was signed by an attorney-in-fact on 08/21/2025 and discloses that breakdowns by price per lot are available upon SEC staff request.
CalciMedica, Inc. reported an insider share purchase by an account associated with its chief business officer and director Eric W. Roberts. On August 15, 2025, a Roth IRA account held at FMTC Custodian for his benefit bought 5,076 shares of CalciMedica common stock in an open‑market transaction at a weighted average price of $2.8977 per share, with individual trade prices ranging from $2.80 to $2.90.
After this transaction, that Roth IRA account held 54,399 CalciMedica shares. The filing also reports 164,706 shares held directly and additional indirect holdings through other Roth IRA and investment entities associated with Roberts.
CalciMedica, Inc. (CALC) reporting person Hebbar Sudarshan, the company's Chief Medical Officer, purchased additional common stock in two transactions. On 08/14/2025 he acquired 1,584 shares at a weighted average price of $2.585, bringing his direct beneficial ownership to 47,584 shares. On 08/15/2025 he acquired 4,392 shares at a weighted average price of $2.793, increasing his direct ownership to 51,976 shares. The filing was signed by an attorney-in-fact on 08/18/2025. The filing includes price ranges for the trades and notes that detailed per-price purchase counts are available on request.
CalciMedica, Inc. filed a Form 8-K reporting that on August 12, 2025 it issued a press release announcing financial results for the fiscal quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and the filing also includes an Inline XBRL cover page as Exhibit 104. The company states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and therefore is not subject to certain liabilities under the federal securities laws.
The report is signed by CEO A. Rachel Leheny, Ph.D.. The filing confirms the Nasdaq ticker CALC and that the registrant identified itself as an emerging growth company.